Bradley J. Fikes, an ever-on-the move ball of energy who roamed the labs of San Diego as the Union-Tribunes biotech writer, chronicling scientists efforts to find ways to alleviate human suffering, died on Wednesday. He was 61.
His family said he passed away of natural causes at his home in Grantville. He had been dividing his time between poring through medical journals and exploring his two other great loves, the San Diego Zoo and Safari Park in Escondido.
Fikes who was part Dr. Dolittle, part Inspector Gadget was especially excited earlier this week as he pulled together a story about two extremely rare platypuses that are being introduced at the zoo.
He talked about it almost non-stop as we drove back and forth between the zoo, said Michelle Guerrero, a Union-Tribune illustrator and graphics reporter. He knew how animals evolve, their relationship with humans, and how they ended up at zoos.
He had the wonderment of a child, the complexity of a scientist and an artful way of coming up with the words to explain it all.
This is the last known photograph of Bradley J. Fikes, the Union-Tribunes biotech writer
(Howard Lipin/The San Diego Union-Tribune)
Fikes was forever in the middle of things, in a literal and figurative sense.
Every Friday, he staked out a table at Bella Vista, a heavily-trafficked cafe between the Salk Institute and UC San Diego. In science, anybody whos anybody and everybody who wants to become somebody hangs out at Bella and networks.
Fikes listened in, took notes, then speed-wrote stories that were devoured by the biotech brigade. Fikes could talk non-stop for 30 minutes about the nature of pluripotent stem cells, then do another half-hour on telomeres and wrap up with some thoughts on chimeras.
He also hung at Bella because of the food. He loved the comfort fare. He loved it so much that Bellas owner, Amanda Caniglia, named a spaghetti dish after him. She called it Il Journalista.
Fikes was impossible to miss. By his own admission, he was a walking fashion disaster. He wore odd-colored business shirts that clashed with his suspenders, and slacks that never made contact with an iron. At times, cellphone cables hung out of his pockets like limp licorice. He feared not having enough power to use his cellphone to watch Black Sabbath and Van Halen videos on YouTube.
People lovingly teased him, hoping for a retort. He often snapped his own suspenders, smiled, and asked, Are you jealous?
News of his death elicited a wave of sorrow and praise Thursday from the countys science industry, whose denizens knew Fikes as a deliciously quirky figure who understood the arcane language of science and the people who are drawn to it.
I always prepped scientists who were meeting him for the first time not to be fooled by the red suspenders and taped glasses, said Chris Emery, communications director at Scripps Research in La Jolla. Bradley is the most legit science reporter youll encounter.
Fikes also was lauded for highlighting the needs and interests of patients, particularly Theresa Blanda and Nancy Davidson, a pair of Orange County women who suffered from debilitating blood cancers.
He followed their cases closely as they sought experimental drugs that might keep them alive. Blanda also supported the biotech companies who were willing to pursue fresh alternatives, even though the outlook was grim.
Blanda later died. But UC San Diego cancer specialist Catriona Jamieson, who helped with the womens treatment, said Fikes was invaluable in telling their stories.
Bradley championed their cause by telling their stories clearly, said Jamieson. He was a serious advocate for patients. He persevered and got difficult stories right. Ive always been a big fan of Bradley.
He was also very keen on gender diversity in life science, said Dawn Barry, president and co-founder of LunaDNA. We lost such a warm, engaged, important San Diego citizen.
Bradley Joseph Fikes was born in San Diego on Jan. 30, 1958, the son of Garland Fikes, a blueprinter, and Trudy Fikes, a nurse who worked at Mercy Hospital.
He learned to read and comprehend difficult information early, which led to a life-shaping moment when he was roughly 6 years old.
Fikes discovered a medical encyclopedia that captivated his attention. One afternoon, he shared the book with neighborhood children, which alarmed their parents because it showed explicit images of the human body.
It was just anatomy; there was nothing wrong with it, said Vanessa Dimalanta, one of Fikes three sisters. That was Brad. Always reading, always sharing with others.
His obsession with science deepened while he was attending San Diego High School and it grew at San Diego State University, where he found his calling journalism.
Like hundreds before him, Fikes joined the Daily Aztec, the campus newspaper, which operated in a raucous newsroom that had male mannequin legs hanging from the ceiling.
This is where he found his tribe, said Karla Peterson, a Union-Tribune columnist who also was part of the Aztec staff.
He loved the work and was at it all of the time. He had so much energy. When we threw parties, Bradley was always the first to arrive and the last to leave. He was happy. He knew how to enjoy life.
Union-Tribune theater critic James Hebert said, He struck me as a total original from the moment I met him like our own slightly mellower answer to Hunter S. Thompson. And it was always resoundingly clear just from being around him that he loved what he did.
After graduating from San Diego State in 1984, Fikes worked as a freelance writer and then spent three years as a staff writer for the Chula Vista Star-News. In 1990, he joined the staff of the San Diego Business Journal, where he worked for six years. Then he spent another year covering business for the San Diego Daily Transcript.
Because of the deep connections he had built in the local business community, Fikes took a brief career detour into corporate communications for a high-tech firm in 1997. He quickly realized his mistake. Despite the higher salary, Fikes missed working as a newspaper journalist. In 1997, he contacted then-North County Times business editor Pam Kragen looking for a staff-writing job. He was hired immediately.
Brad had a bit of the nutty professor about him when it came to style, but his brain worked like a computer, Kragen said.
He was able to store vast amounts of information and call on it to write knowledgeably, accurately, quickly and prolifically. After returning to the newspaper business, I remember Brad telling me that all he ever really wanted to do was to be a journalist because he loved the process of discovering something new and then sharing it with readers. He was very proud to work at the Union-Tribune.
He loved the job and the newsroom was his home.
Union-Tribune Publisher and Editor Jeff Light said, Bradley had a rare combination of intellect, curiosity and character. It made him a wonderful journalist.
By character, I mean the strength to be true to himself. But he also had a vulnerability that made you feel protective of him. He was a beloved figure. Our newsroom will miss him terribly.
Fikes is survived by three sisters, Sue Tate of San Diego; Vanessa Dimalanta of San Diego, and Kimberley Cross of San Diego.
Originally posted here:
Union-Tribune biotech writer Bradley J. Fikes, beloved by colleagues, dies at 61 - The San Diego Union-Tribune
- Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live - November 26th, 2023
- What Is Amyloidosis? All About The Rare Disease That Pervez Musharraf Suffered From - ABP Live - February 8th, 2023
- Autophagic death of neural stem cells mediates chronic stress-induced ... - November 7th, 2022
- Programmed cell death - Wikipedia - November 7th, 2022
- Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions - September 4th, 2022
- Canadian Blood Services Stem Cells for Life - September 4th, 2022
- Devastation over death of schoolgirl, 11, who hoped she was beating cancer - Leicestershire Live - September 4th, 2022
- From optimized stem cell transplants to CAR T cell therapy: Advancing options for cancer, HIV and more - City of Hope - September 4th, 2022
- Scientists unlock the key to immortality in jellyfish - Syfy - September 4th, 2022
- Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients... - September 4th, 2022
- Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AML - Targeted Oncology - September 4th, 2022
- Wanted murder suspect John Belfield believed to still be in the UK as two more arrested over death of Thomas Campbell - The Manc - September 4th, 2022
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022
- Can minds persist when they are cut off from the world? - Livescience.com - July 8th, 2022
- Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population - Cancer Network - July 8th, 2022
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022
- How abortion ruling could affect IVF and embryonic research - The Almanac Online - July 8th, 2022
- This Morning viewers 'in tears' after boy meets donor who saved his life - Devon Live - July 8th, 2022
- Alpena detective: 'Good people out there' | News, Sports, Jobs - Alpena News - July 8th, 2022
- 'I miss my best friend': Five-year-old runs 10k to honour girl who died from rare brain tumour - Teesside Live - July 8th, 2022
- Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by... - July 8th, 2022
- Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc - Yahoo Finance - July 8th, 2022
- A New Strategy Could Turn the Tide in Stem Cell GVHD - Medical Device and Diagnostics Industry - January 17th, 2022
- Vertex type 1 diabetes vs stem cell therapy - The Boar - January 17th, 2022
- Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT - AJMC.com Managed Markets Network - January 17th, 2022
- Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL - Targeted Oncology - January 17th, 2022
- Psaki demolishes Doocy with stats as he tries to claim covid now an illness of the vaccinated - newsconcerns - January 17th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 17th, 2022
- Who does donated blood that's direly needed help? - WTOP - January 17th, 2022
- Places Where Omicron is Most Contagious Eat This Not That - Eat This, Not That - January 17th, 2022
- UHN and U of T receive $24-million federal grant for transplant research - News@UofT - January 17th, 2022
- Glycyrrhizic acid ameliorates submandibular gland oxidative stress, autophagy and vascular dysfunction in rat model of type 1 diabetes | Scientific... - January 17th, 2022
- Stem cells in cancer therapy: opportunities and challenges - January 1st, 2022
- Life After Brain Death: Is the Body Still 'Alive'? | Live ... - January 1st, 2022
- Autologous Adult Stem Cells in the Treatment of Stroke | SCCAA - Dove Medical Press - January 1st, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 1st, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 1st, 2022
- Upregulated expression of actin-like 6A is a risk factor | CMAR - Dove Medical Press - January 1st, 2022
- COVID-19 Takes a Toll on People with Blood Cancers and Disorders - Cancer Health Treatment News - January 1st, 2022
- Mental health disorders and heart diseases - Rising Kashmir - January 1st, 2022
- Research breakthrough could mean better treatment for patients with most deadly form of brain tumor - EurekAlert - October 26th, 2021
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable... - October 26th, 2021
- European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Galveston County Daily News - October 26th, 2021
- Everything You Need To Know About COVID Booster Shots - Colorado Times Recorder - October 26th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Will humans ever be immortal? - Livescience.com - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - ABC 12 News - October 5th, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 5th, 2021
- Skeletons' broken clavicles tell a centuries-old tale of humans and horses - Massive Science - October 5th, 2021
- Environmental Factor - August 2021: Extramural Papers of the Month - Environmental Factor Newsletter - August 4th, 2021
- Role of traumatic brain injury in the development of glioma | JIR - Dove Medical Press - August 4th, 2021
- Targeted Therapeutics Market: Increase in Incidence of Cancer to Drive Global Market - BioSpace - August 4th, 2021
- Accumulation of Regulatory T Cells in Triple Negative Breast Cancer Ca | CMAR - Dove Medical Press - August 4th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 7th, 2021
- Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver - Science Advances - June 7th, 2021
- Cancer research: New advances and innovations - Medical News Today - June 7th, 2021
- Fulvestrant Alone Found to be Superior to Venetoclax/Fulvestrant Combo in ER+/HER2- Breast Cancer - Targeted Oncology - June 7th, 2021
- Merck's KEYTRUDA Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal... - June 7th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 14th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV (enfortumab vedotin-ejfv) in Patients with Previously... - February 14th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 14th, 2021
- The drug treatments offering the best hope of a way out of the Covid crisis - Telegraph.co.uk - February 14th, 2021
- In the war against Covid, an arsenal of drugs is on the way - Telegraph.co.uk - February 14th, 2021
- Kat Wests husband, Jeff West, sentenced to 16 years in wifes death - AL.com - February 9th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 9th, 2021
- I Survived Cancer, and Then I Needed to Remember How to Live - The Atlantic - February 9th, 2021
- [Full text] Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor f | CMAR - Dove Medical Press - February 9th, 2021
- West Belfast woman to be remembered in special TV documentary - Belfast Live - January 29th, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - January 29th, 2021
- L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology - January 29th, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - January 29th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 29th, 2021
- Experimental taphonomy of organelles and the fossil record of early eukaryote evolution - Science Advances - January 29th, 2021